Abbott India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
February 10, 2023 at 02:01 pm IST
Share
Abbott India Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 13,264.8 million compared to INR 12,243.6 million a year ago. Revenue was INR 13,664.2 million compared to INR 12,431 million a year ago. Net income was INR 2,468.3 million compared to INR 1,992 million a year ago. Basic earnings per share from continuing operations was INR 116.16 compared to INR 93.74 a year ago.
For the nine months, sales was INR 40,103.3 million compared to INR 36,642.5 million a year ago. Revenue was INR 41,101.6 million compared to INR 37,204.1 million a year ago. Net income was INR 7,179.9 million compared to INR 5,872.9 million a year ago. Basic earnings per share from continuing operations was INR 337.88 compared to INR 276.37 a year ago.
Abbott India Limited is an India-based company that is engaged in the pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolic, multi-specialty, and vaccines, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), Duvadilan (preterm labor), and others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure, Glucerna, and others.